AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23333819 — intervention group
Group type: EXPERIMENTAL
Intervention: 10s breath-hold maneuvers (0.28% CO)
Number of subjects: 9
Study 23333819 — intervention group
Group type: EXPERIMENTAL
Intervention: 5s breath-hold maneuvers
Number of subjects: 9
Study 21378174 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (6.0 mg/kg)
Number of subjects: 11
Study 21378174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 20069257 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing bite splints
Number of subjects: 31
Study 20069257 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning splints
Number of subjects: 31
Study 18202966 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA 0.1
Number of subjects: 575
Study 18202966 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA 0.25
Number of subjects: 575
Study 18202966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 18202966 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (E2/NETA 0.1, E2/NETA 0.25, Placebo)
Number of subjects: 575
Study 16214436 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic LVH
Number of subjects: 273
Study 12171821 — intervention group
Group type: EXPERIMENTAL
Intervention: IV magnesium sulfate (2 grams)
Number of subjects: 248
Study 12171821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 10578225 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/daily) + Hydrochlorothiazide (25 mg/daily)
Number of subjects: 14
Study 10578225 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/daily) + Indapamide (2.5 mg/daily)
Number of subjects: 14
Study 10578225 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (4 mg/daily)
Number of subjects: 14
Study 10578225 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/daily)
Number of subjects: 14
Study 10578225 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/daily)
Number of subjects: 14
Study 10578225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P + HCT
Number of subjects: 14
Study 10578225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of P + IND
Number of subjects: 14
Study 7788038 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release isosorbide-5-nitrate
Number of subjects: 30
Study 7788038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2195346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone for 6 weeks followed by 5 million units of recombinant interferon alfa‐2b daily for 16 weeks
Number of subjects: 168
Study 849691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with BCG and chemotherapy
Number of subjects: 0
Study 849691 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 31693643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (20 min, 2 d/wk)
Number of subjects: 70
Study 31693643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume HIIT (40 min, 2 d/wk)
Number of subjects: 70
Study 31693643 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) group (physical activity recommendations, n = 14)
Number of subjects: 70
Study 31600397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and Bevacizumab
Number of subjects: 38
Study 28391289 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered sleep intervention (sleep-hygiene education, stimulus control, and cognitive behavioral therapy)
Number of subjects: 134
Study 28391289 — intervention group
Group type: COMPARATOR
Intervention: Control group (vascular risk factor education)
Number of subjects: 134
Study 28391289 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered sleep intervention
Number of subjects: 134
Study 25500986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 78
Study 25500986 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 78
Study 24160217 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by a health professional
Number of subjects: 107
Study 24160217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 107
Study 21454798 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 and 300 mg once daily)
Number of subjects: 50
Study 21454798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21454798 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 50
Study 21454798 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 50
Study 21454798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 50
Study 17988832 — intervention group
Group type: EXPERIMENTAL
Intervention: GCBT+EX (Group Cognitive Behavioral Therapy + Exercise)
Number of subjects: 74
Study 17988832 — intervention group
Group type: COMPARATOR
Intervention: GCBT+ED (Group Cognitive Behavioral Therapy + Education)
Number of subjects: 74
Study 17039901 — intervention group
Group type: COMPARATOR
Intervention: Fibrates
Number of subjects: 100
Study 17039901 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 100
Study 14706902 — intervention group
Group type: EXPERIMENTAL
Intervention: Caelyx
Number of subjects: 474
Study 14706902 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 474
Study 11023504 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐CdA + prednisone (P)
Number of subjects: 229
Study 11023504 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (Chl) + prednisone (P)
Number of subjects: 229
Study 8836985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day) for 8 weeks
Number of subjects: 19
Study 1466463 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lumbar fentanyl
Number of subjects: 50
Study 1466463 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural thoracic fentanyl
Number of subjects: 50
Study 1466463 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 50
Study 6373154 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (250 micrograms)
Number of subjects: 20
Study 6373154 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (500 micrograms)
Number of subjects: 20
Study 6373154 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (250 mg)
Number of subjects: 20
Study 30770432 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred algorithm requiring ≥3 MS-related claims from any combination of inpatient, outpatient, or DMT claims within a 1-year time period.
Number of subjects: 4
Study 30770432 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred algorithm tested in Saskatchewan cohort from the general population.
Number of subjects: 4
Study 30770432 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms including DMT claims.
Number of subjects: 4
Study 29790072 — intervention group
Group type: EXPERIMENTAL
Intervention: Social comparison feedback (e-mailed summary of routine laboratory test ordering vs. service average for the prior week, linked to a personalized dashboard)
Number of subjects: 114
Study 29790072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 114
Study 29790072 — intervention group
Group type: EXPERIMENTAL
Intervention: Social comparison feedback for physicians whose absolute ordering rate deviated from the peer rate by more than 1.0 laboratory test per patient-day
Number of subjects: 114
Study 28033279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm clipping plus fenestration of lamina terminalis (FLT)
Number of subjects: 288
Study 28033279 — intervention group
Group type: COMPARATOR
Intervention: Single aneurysm clipping
Number of subjects: 288
Study 28033279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm clipping plus FLT
Number of subjects: 288
Study 25296586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention focused on plant foods with a low glycemic load, low in saturated fats and alcohol, and rich in antioxidants and fiber.
Number of subjects: 234
Study 25296586 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention based on moderate‐intensity PA.
Number of subjects: 234
Study 25296586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Physical Activity intervention.
Number of subjects: 234
Study 25296586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 234
Study 22373589 — intervention group
Group type: COMPARATOR
Intervention: Group S + S: normal saline 0.15 ml/kg + normal saline 0.06 ml/kg
Number of subjects: 440
Study 22373589 — intervention group
Group type: COMPARATOR
Intervention: Group S + M: normal saline 0.15 ml/kg + midazolam 0.06 mg/kg
Number of subjects: 440
Study 22373589 — intervention group
Group type: COMPARATOR
Intervention: Group D + S: dexmedetomidine 0.6 μg/kg + normal saline 0.06 ml/kg
Number of subjects: 440
Study 22373589 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D + M: dexmedetomidine 0.6 μg/kg + midazolam 0.06 mg/kg
Number of subjects: 440
Study 20833658 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-diuretics association
Number of subjects: 270
Study 20833658 — intervention group
Group type: COMPARATOR
Intervention: Diuretics alone
Number of subjects: 270
Study 18821668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18821668 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1,000 mg/day)
Number of subjects: 18
Study 18821668 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (2,000 IU/day)
Number of subjects: 18
Study 18821668 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 plus Calcium (1,000 mg/day)
Number of subjects: 18
Study 15774435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath based treatment (BB)
Number of subjects: 120
Study 15774435 — intervention group
Group type: COMPARATOR
Intervention: Movement science based treatment (MSB)
Number of subjects: 120
Study 12444814 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (225 to 350 mg/day)
Number of subjects: 73
Study 12444814 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (150 to 225 mg/day)
Number of subjects: 73
Study 12444814 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 73
Study 12444814 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 73
Study 10343140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron saccharate for 8 weeks
Number of subjects: 20
Study 10343140 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin in patients without response after iron treatment
Number of subjects: 20
Study 8952658 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 0
Study 8952658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 0
Study 1935353 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-praziquantel (L-PZQ) at 20 mg/kg
Number of subjects: 278
Study 1935353 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (PZQ) at 40 mg/kg
Number of subjects: 278
Study 6460467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine (maximum dosage of 200 mg per day for three or more weeks)
Number of subjects: 19
Study 6460467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30488957 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiration Control (RESP)
Number of subjects: 547
Study 30488957 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Tension (AT)
Number of subjects: 547
Study 30488957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AT and RESP
Number of subjects: 547
Study 30488957 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 547
Study 29590421 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 120
Study 29590421 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 120
Study 29590421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 27299450 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration with ropivacaine, epinephrine, ketorolac, and clonidine
Number of subjects: 100
Study 27299450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24622951 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Valsalva manoeuvre (VM) with leg elevation and supine posture
Number of subjects: 372
Study 24622951 — intervention group
Group type: COMPARATOR
Intervention: Standard Valsalva manoeuvre (VM)
Number of subjects: 372
Study 23373268 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose albumin group
Number of subjects: 0
Study 23373268 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive group
Number of subjects: 0
Study 23373268 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 0
Study 23373268 — intervention group
Group type: COMPARATOR
Intervention: High-dose diuretic group
Number of subjects: 0
Study 20429825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster
Number of subjects: 0
Study 20429825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 20429825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5% lidocaine medicated plaster and pregabalin
Number of subjects: 0
Study 20429825 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17647117 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser (FS) for LASIK
Number of subjects: 485
Study 15991509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 45
Study 15991509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 45
Study 15991509 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 45
Study 12045777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine 15 mg daily
Number of subjects: 30
Study 12045777 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalamine 800 mg tid
Number of subjects: 30
Study 10203619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received mailed feedback intervention)
Number of subjects: 0
Study 10203619 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive the intervention)
Number of subjects: 0
Study 7617534 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical function for plasma concentration convolved with a monoexponential function to generate effect site concentration.
Number of subjects: 0
Study 7617534 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect site concentration and time as independent variables in the model for logit of probability of specific PR score pre-remedication.
Number of subjects: 0
Study 2217349 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg per day (first 10 days)
Number of subjects: 1
Study 2217349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (next 25 days)
Number of subjects: 1
Study 2217349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three tablets per day for one week)
Number of subjects: 1
Study 2217349 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in the morning, noon, or evening (subsequent weeks)
Number of subjects: 1
Study 2217349 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication (after 10 years of treatment)
Number of subjects: 1
Study 389262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor
Number of subjects: 104
Study 389262 — intervention group
Group type: COMPARATOR
Intervention: Propylene glycol
Number of subjects: 104
Study 31558730 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep condition
Number of subjects: 0
Study 31558730 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep condition
Number of subjects: 0
Study 31558730 — intervention group
Group type: COMPARATOR
Intervention: Attention lapses after either sleep manipulation
Number of subjects: 0
Study 28875459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol 100 µg/62.5 µg/25 µg
Number of subjects: 1810
Study 28875459 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol 400 µg/12 µg
Number of subjects: 1810
Study 26195173 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision support tool
Number of subjects: 125
Study 26195173 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study 22750997 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 251
Study 22750997 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin in TBI recipients
Number of subjects: 251
Study 20440568 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (48-hour on-off medication protocol)
Number of subjects: 28
Study 20440568 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 28
Study 20440568 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD children (on medication)
Number of subjects: 28
Study 20440568 — intervention group
Group type: COMPARATOR
Intervention: ADHD children and control children
Number of subjects: 28
Study 19587265 — intervention group
Group type: EXPERIMENTAL
Intervention: OXT (1 pmol/kg per min over 90 min)
Number of subjects: 10
Study 19587265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16924215 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial back education program
Number of subjects: 193
Study 16924215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 193
Study 14989751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-NiTi archwires with a transition temperature of 40 degrees C
Number of subjects: 15
Study 14989751 — intervention group
Group type: COMPARATOR
Intervention: Cu-NiTi archwires with a transition temperature of 27 degrees C
Number of subjects: 15
Study 11350752 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (500 mg of vitamin C and 400 mg of vitamin E)
Number of subjects: 20
Study 11350752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11350752 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 20
Study 10997544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A/beta-carotene supplementation
Number of subjects: 10422
Study 10997544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10422
Study 10997544 — intervention group
Group type: EXPERIMENTAL
Intervention: Night blindness
Number of subjects: 10422
Study 9036201 — intervention group
Group type: EXPERIMENTAL
Intervention: chronotherapy with heparin and curantyl added to traditional therapy
Number of subjects: 112
Study 9036201 — intervention group
Group type: COMPARATOR
Intervention: traditional therapy
Number of subjects: 112
Study 1321177 — intervention group
Group type: EXPERIMENTAL
Intervention: First-hour skin chamber fluids (CF) from antigen challenge
Number of subjects: 0
Study 1321177 — intervention group
Group type: COMPARATOR
Intervention: First-hour buffer-site CF
Number of subjects: 0
Study 1321177 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline
Number of subjects: 0
Study 6383790 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide (19.3‐36 mg/kg/day)
Number of subjects: 15
Study 6383790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30900408 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT+Lifestyle
Number of subjects: 185
Study 30900408 — intervention group
Group type: COMPARATOR
Intervention: Standard PAT
Number of subjects: 185
Study 30268966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training with blood flow restriction (LLRT-BFR)
Number of subjects: 40
Study 30268966 — intervention group
Group type: COMPARATOR
Intervention: Low-load resistance training (LLRT)
Number of subjects: 40
Study 27342914 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose 2007 Southern Hemisphere trivalent inactivated influenza vaccine formulated with Advax™ delta inulin adjuvant (LTIV+Adj)
Number of subjects: 100
Study 27342914 — intervention group
Group type: COMPARATOR
Intervention: Full-dose standard TIV vaccine (no adjuvant)
Number of subjects: 100
Study 27342914 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose TIV vaccine containing Advax adjuvant
Number of subjects: 100
Study 27342914 — intervention group
Group type: COMPARATOR
Intervention: Standard TIV vaccine
Number of subjects: 100
Study 24676998 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 25-150 mg eq. injected intramuscularly in deltoid muscle
Number of subjects: 201
Study 24676998 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 25-150 mg eq. injected intramuscularly in gluteal muscle
Number of subjects: 201
Study 22490266 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic assertive community treatment (ACT)
Number of subjects: 120
Study 22490266 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 19808912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 30
Study 19808912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19808912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sativex and Placebo)
Number of subjects: 30
Study 17400681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BPAP) for 3 months, daily use of 4.8 +/- 0.3 hours
Number of subjects: 52
Study 17400681 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 52
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral Minocin MR (minocycline) once daily (o.d.)
Number of subjects: 649
Study 15588555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined erythromycin (2% erythromycin) and benzoyl peroxide (5% benzoyl peroxide) formulation
Number of subjects: 649